WO2014015153A3 - Treating ewing's sarcoma and ews-fli1 related disorders - Google Patents

Treating ewing's sarcoma and ews-fli1 related disorders Download PDF

Info

Publication number
WO2014015153A3
WO2014015153A3 PCT/US2013/051105 US2013051105W WO2014015153A3 WO 2014015153 A3 WO2014015153 A3 WO 2014015153A3 US 2013051105 W US2013051105 W US 2013051105W WO 2014015153 A3 WO2014015153 A3 WO 2014015153A3
Authority
WO
WIPO (PCT)
Prior art keywords
fli1
ews
sarcoma
related disorders
treating ewing
Prior art date
Application number
PCT/US2013/051105
Other languages
French (fr)
Other versions
WO2014015153A2 (en
Inventor
Ramani AIYER
James E. O'DORISIO
Original Assignee
Star Biotechnology, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Star Biotechnology, Llc filed Critical Star Biotechnology, Llc
Priority to MX2015000804A priority Critical patent/MX2015000804A/en
Priority to US14/415,705 priority patent/US20150174097A1/en
Publication of WO2014015153A2 publication Critical patent/WO2014015153A2/en
Publication of WO2014015153A3 publication Critical patent/WO2014015153A3/en
Priority to US15/341,655 priority patent/US20170165231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The field relates to compositions and methods for treating Ewing's Sarcoma and other disorders related to EWS-FLI1.
PCT/US2013/051105 2012-07-20 2013-07-18 Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 WO2014015153A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2015000804A MX2015000804A (en) 2012-07-20 2013-07-18 Treating ewing's sarcoma and ews-fli1 related disorders.
US14/415,705 US20150174097A1 (en) 2012-07-20 2013-07-18 Treating ewing's sarcoma and ews-fli1 related disorders
US15/341,655 US20170165231A1 (en) 2012-07-20 2016-11-02 Treating ewing's sarcoma and ews-fli1 related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674047P 2012-07-20 2012-07-20
US61/674,047 2012-07-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/415,705 A-371-Of-International US20150174097A1 (en) 2012-07-20 2013-07-18 Treating ewing's sarcoma and ews-fli1 related disorders
US15/341,655 Continuation US20170165231A1 (en) 2012-07-20 2016-11-02 Treating ewing's sarcoma and ews-fli1 related disorders

Publications (2)

Publication Number Publication Date
WO2014015153A2 WO2014015153A2 (en) 2014-01-23
WO2014015153A3 true WO2014015153A3 (en) 2014-05-01

Family

ID=49949378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/051105 WO2014015153A2 (en) 2012-07-20 2013-07-18 Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1

Country Status (2)

Country Link
MX (1) MX2015000804A (en)
WO (1) WO2014015153A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6654197B2 (en) * 2014-10-09 2020-02-26 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Indolinone compounds and uses thereof
KR102375929B1 (en) * 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. Indoline analogs and uses thereof
EP3490553A4 (en) 2016-07-29 2020-03-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
US20070009484A1 (en) * 2005-02-08 2007-01-11 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US20090286752A1 (en) * 2008-05-15 2009-11-19 Etter Jeffrey B Oral formulations of cytidine analogs and methods of use thereof
US20100167994A1 (en) * 2006-12-29 2010-07-01 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
WO2012019284A1 (en) * 2010-08-11 2012-02-16 Universite De Montreal Combinatory cancer treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
US20070009484A1 (en) * 2005-02-08 2007-01-11 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US20100167994A1 (en) * 2006-12-29 2010-07-01 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US20090286752A1 (en) * 2008-05-15 2009-11-19 Etter Jeffrey B Oral formulations of cytidine analogs and methods of use thereof
WO2012019284A1 (en) * 2010-08-11 2012-02-16 Universite De Montreal Combinatory cancer treatment

Also Published As

Publication number Publication date
MX2015000804A (en) 2016-03-11
WO2014015153A2 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
JO3343B1 (en) Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
WO2015073587A3 (en) Synthetic membrane-receiver complexes
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
IL241191B (en) Topical compositions and kits comprising the same for treating topical disorders
MX2016004927A (en) Compositions useful for treating disorders related to kit.
MX2019008122A (en) Heterocycle amines and uses thereof.
WO2014194034A3 (en) Novel metalloproteases
IL238876A0 (en) Indoleamine 2,3-dioxygenase inhibitors, compositions comprising the same and uses thereof
EP2552433A4 (en) Compositions and methods for the treatment of somatosensory disorders
IL283432A (en) Compositions, methods and systems for the treatment of cutaneous disorders
MY189912A (en) Substituted xanthines and methods of use thereof
HK1193100A1 (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament -3--[310]-3--
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
EP3008167A4 (en) Compositions and methods for treating metabolic disorders
WO2012027482A3 (en) Compounds, compositions and methods related to ppar antagonists
ZA201402795B (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
WO2016001885A3 (en) Amorphous form of eliglustat hemitartarate
IN2014DN11078A (en)
WO2014015153A3 (en) Treating ewing's sarcoma and ews-fli1 related disorders
WO2016012938A3 (en) Improved process for preparation of amorphous linaclotide
IL234616A0 (en) Herbal composition for the treatment of metabolic disorders
EP3011336A4 (en) Methods, systems, and composition related to neural disorders
EP2999464A4 (en) Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms
CA144318S (en) Filter
WO2015120334A3 (en) Compositions and methods for treating neurological disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13820703

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/000804

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 14415705

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13820703

Country of ref document: EP

Kind code of ref document: A2